Clinical Trials Logo
  1. Home
  2. Cachexia
  3. NCT05623852

The Impact of Oligo-Fucoidan in Cancer Cachexia and Sarcopenia — OFCS  

Cachexia Clinical Trial

Official title:
A Phase II Trial for Oligo-Fucoidan in Cancer Cachexia and Sarcopenia

Clinical Trial Summary

Fucoidan also ameliorates tumour and chemotherapy-induced muscle atrophy and -related cachectic symptoms in vivo and in vitro. To evaluate the effect of fucoidan in cancer cachexia or sarcopenia in cancer patients.

Clinical Trial Description

Cancer cachexia is characterized by anorexia, skeletal muscle atrophy, and systemic inflammation. Fucoidan extracted from brown algae exhibits anti-inflammatory and anticancer activities. In addition, fucoidan also ameliorates tumour and chemotherapy-induced muscle atrophy and -related cachectic symptoms in vivo and in vitro. To evaluate the effect of fucoidan in cancer cachexia or sarcopenia in cancer patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05623852
Study type Interventional
Source Taipei Medical University WanFang Hospital
Contact Szu-Yuan Wu
Phone +886910603955
Email szuyuanwu5399@gmail.com
Status Recruiting
Phase N/A
Start date January 30, 2022
Completion date April 30, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05603585 - Optimal Protein Supplementation and Early Exercise In Mechanically Ventilated Patients N/A
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Completed NCT01696604 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT02567773 - Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078 Phase 1
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2
Active, not recruiting NCT00710632 - Screening to Predict Weight Loss in Patients With Cancer N/A
Completed NCT00031785 - Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer Phase 3
Withdrawn NCT02017925 - Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation N/A
Recruiting NCT01829880 - Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure N/A
Completed NCT01419145 - A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study N/A
Completed NCT01692990 - Study on the Effect of Fish Oil and Appetite Phase 0
Terminated NCT00851448 - Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients N/A
Terminated NCT00962234 - Metabolism of Lipids in Advanced Cancer N/A
Completed NCT00994669 - Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients N/A
Completed NCT01015274 - Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients
Completed NCT00972634 - Computerized Questionnaires in Assessing Symptoms, Pain, Depression, and Physical Function in Patients With Metastatic and/or Advanced Locoregional Cancer N/A
Terminated NCT00558558 - Haelan and Nutrition in Cancer Patients Phase 2
Terminated NCT00535015 - Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer Phase 2